Omalizumab is approved for severe asthma in patients aged 6 yr or older with uncontrolled asthma, elevated total IgE, and sensitization to a perennial aeroallergen by skin-prick test or serum-specific IgE. The gene discussed is IGHE; the disease is asthma.